Cargando…
Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial whe...
Autores principales: | Rodríguez Meza, Miguel Ricardo, Nakamura, Masanao, Yamamura, Takeshi, Maeda, Keiko, Sawada, Tsunaki, Ishikawa, Eri, Kakushima, Naomi, Furukawa, Kazuhiro, Iida, Tadashi, Mizutani, Yasuyuki, Ishikawa, Takuya, Ohno, Eizaburo, Honda, Takashi, Kawashima, Hiroki, Ishigami, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nagoya University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748329/ https://www.ncbi.nlm.nih.gov/pubmed/36544593 http://dx.doi.org/10.18999/nagjms.84.4.733 |
Ejemplares similares
-
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022) -
Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis
por: Maeda, Keiko, et al.
Publicado: (2022) -
Diagnostic performance of endoscopic classifications for neoplastic lesions in patients with ulcerative colitis: A retrospective case-control study
por: Kida, Yuichi, et al.
Publicado: (2022) -
Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020) -
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)